The first chemically-synthesised, highly immunogenic anti-SARS-CoV 2 peptides in DNA genotyped aotus monkeys for human use

ABSTRACT: Thirty-five peptides selected from functionally-relevant SARS-CoV-2 spike (S), membrane (M), and envelope (E) proteins were suitably modified for immunising MHC class II (MHCII) DNA-genotyped Aotus monkeys and matched with HLA-DRb1* molecules for use in humans. This was aimed at producing...

Full description

Autores:
Rugeles López, María Teresa
Aguilar Jiménez, Wbeimar
Flórez Álvarez, Lizdany
Pabón, Laura
Patarroyo, Manuel Elkin
Patarroyo, Manuel Alonso
Alba, Martha P.
Bermúdez, Abriana
Rout, Ashok k.
Griesinger, Cristina
Suarez Martínez, Carlos Fernando
Aza Conde, Jorge
Reyes, Cesar
Avendaño, Catalina
Samacá, Jhoan
Camargo, Anny
Silva, Yolanda
Forero, Martha
González, Edgardo
Tipo de recurso:
Article of investigation
Fecha de publicación:
2021
Institución:
Universidad de Antioquia
Repositorio:
Repositorio UdeA
Idioma:
eng
OAI Identifier:
oai:bibliotecadigital.udea.edu.co:10495/36775
Acceso en línea:
https://hdl.handle.net/10495/36775
Palabra clave:
SARS-CoV-2
Péptidos
Peptides
Anticuerpos ampliamente neutralizantes
Broadly Neutralizing Antibodies
Anticuerpos Virales
Antibodies, Viral
Vacunas contra la COVID-19
COVID-19 Vaccines
Cadenas HLA-DRB1
HLA-DRB1 Chains
Glicoproteína de la Espiga del Coronavirus
Spike Glycoprotein, Coronavirus
Virosis
Virus Diseases
Rights
openAccess
License
http://creativecommons.org/licenses/by/2.5/co/
id UDEA2_2762d1a3ef3564754dea6ac42b9c5c5b
oai_identifier_str oai:bibliotecadigital.udea.edu.co:10495/36775
network_acronym_str UDEA2
network_name_str Repositorio UdeA
repository_id_str
dc.title.spa.fl_str_mv The first chemically-synthesised, highly immunogenic anti-SARS-CoV 2 peptides in DNA genotyped aotus monkeys for human use
title The first chemically-synthesised, highly immunogenic anti-SARS-CoV 2 peptides in DNA genotyped aotus monkeys for human use
spellingShingle The first chemically-synthesised, highly immunogenic anti-SARS-CoV 2 peptides in DNA genotyped aotus monkeys for human use
SARS-CoV-2
Péptidos
Peptides
Anticuerpos ampliamente neutralizantes
Broadly Neutralizing Antibodies
Anticuerpos Virales
Antibodies, Viral
Vacunas contra la COVID-19
COVID-19 Vaccines
Cadenas HLA-DRB1
HLA-DRB1 Chains
Glicoproteína de la Espiga del Coronavirus
Spike Glycoprotein, Coronavirus
Virosis
Virus Diseases
title_short The first chemically-synthesised, highly immunogenic anti-SARS-CoV 2 peptides in DNA genotyped aotus monkeys for human use
title_full The first chemically-synthesised, highly immunogenic anti-SARS-CoV 2 peptides in DNA genotyped aotus monkeys for human use
title_fullStr The first chemically-synthesised, highly immunogenic anti-SARS-CoV 2 peptides in DNA genotyped aotus monkeys for human use
title_full_unstemmed The first chemically-synthesised, highly immunogenic anti-SARS-CoV 2 peptides in DNA genotyped aotus monkeys for human use
title_sort The first chemically-synthesised, highly immunogenic anti-SARS-CoV 2 peptides in DNA genotyped aotus monkeys for human use
dc.creator.fl_str_mv Rugeles López, María Teresa
Aguilar Jiménez, Wbeimar
Flórez Álvarez, Lizdany
Pabón, Laura
Patarroyo, Manuel Elkin
Patarroyo, Manuel Alonso
Alba, Martha P.
Bermúdez, Abriana
Rout, Ashok k.
Griesinger, Cristina
Suarez Martínez, Carlos Fernando
Aza Conde, Jorge
Reyes, Cesar
Avendaño, Catalina
Samacá, Jhoan
Camargo, Anny
Silva, Yolanda
Forero, Martha
González, Edgardo
dc.contributor.author.none.fl_str_mv Rugeles López, María Teresa
Aguilar Jiménez, Wbeimar
Flórez Álvarez, Lizdany
Pabón, Laura
Patarroyo, Manuel Elkin
Patarroyo, Manuel Alonso
Alba, Martha P.
Bermúdez, Abriana
Rout, Ashok k.
Griesinger, Cristina
Suarez Martínez, Carlos Fernando
Aza Conde, Jorge
Reyes, Cesar
Avendaño, Catalina
Samacá, Jhoan
Camargo, Anny
Silva, Yolanda
Forero, Martha
González, Edgardo
dc.contributor.researchgroup.spa.fl_str_mv Inmunovirología
dc.subject.decs.none.fl_str_mv SARS-CoV-2
Péptidos
Peptides
Anticuerpos ampliamente neutralizantes
Broadly Neutralizing Antibodies
Anticuerpos Virales
Antibodies, Viral
Vacunas contra la COVID-19
COVID-19 Vaccines
Cadenas HLA-DRB1
HLA-DRB1 Chains
Glicoproteína de la Espiga del Coronavirus
Spike Glycoprotein, Coronavirus
Virosis
Virus Diseases
topic SARS-CoV-2
Péptidos
Peptides
Anticuerpos ampliamente neutralizantes
Broadly Neutralizing Antibodies
Anticuerpos Virales
Antibodies, Viral
Vacunas contra la COVID-19
COVID-19 Vaccines
Cadenas HLA-DRB1
HLA-DRB1 Chains
Glicoproteína de la Espiga del Coronavirus
Spike Glycoprotein, Coronavirus
Virosis
Virus Diseases
description ABSTRACT: Thirty-five peptides selected from functionally-relevant SARS-CoV-2 spike (S), membrane (M), and envelope (E) proteins were suitably modified for immunising MHC class II (MHCII) DNA-genotyped Aotus monkeys and matched with HLA-DRb1* molecules for use in humans. This was aimed at producing the first minimal subunit-based, chemically synthesised, immunogenic molecules (COLSARSPROT) covering several HLA alleles. They were predicted to cover 48.25% of the world’s population for 6 weeks (short-term) and 33.65% for 15 weeks (long-lasting) as they induced very high immunofluorescent antibody (IFA) and ELISA titres against S, M and E parental native peptides, SARS-CoV-2 neutralising antibodies and host cell infection. The same immunological methods that led to identifying new peptides for inclusion in the COLSARSPROT mixture were used for antigenicity studies. Peptides were analysed with serum samples from patients suffering mild or severe SARS-CoV-2 infection, thereby increasing chemically-synthesised peptides’ potential coverage for the world populations up to 62.9%. These peptides’ 3D structural analysis (by 1 H-NMR acquired at 600 to 900 MHz) suggested structural functional immunological association. This first multi-protein, multi-epitope, minimal subunit-based, chemically-synthesised, highly immunogenic peptide mixture highlights such chemical synthesis methodology’s potential for rapidly obtaining very pure, highly reproducible, stable, cheap, easily-modifiable peptides for inducing immune protection against COVID-19, covering a substantial percentage of the human population.
publishDate 2021
dc.date.issued.none.fl_str_mv 2021
dc.date.accessioned.none.fl_str_mv 2023-10-03T15:48:19Z
dc.date.available.none.fl_str_mv 2023-10-03T15:48:19Z
dc.type.spa.fl_str_mv Artículo de investigación
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.redcol.spa.fl_str_mv https://purl.org/redcol/resource_type/ART
dc.type.coarversion.spa.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/article
dc.type.version.spa.fl_str_mv info:eu-repo/semantics/publishedVersion
format http://purl.org/coar/resource_type/c_2df8fbb1
status_str publishedVersion
dc.identifier.citation.spa.fl_str_mv Patarroyo ME, Patarroyo MA, Alba MP, Pabon L, Rugeles MT, Aguilar-Jimenez W, Florez L, Bermudez A, Rout AK, Griesinger C, Suarez CF, Aza-Conde J, Reyes C, Avendaño C, Samaca´ J, Camargo A, Silva Y, Forero M and Gonzalez E (2021) The First Chemically Synthesised, Highly Immunogenic Anti-SARS-CoV-2 Peptides in DNA Genotyped Aotus Monkeys for Human Use. Front. Immunol. 12:724060.
dc.identifier.issn.none.fl_str_mv 1664-3224
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/10495/36775
dc.identifier.doi.none.fl_str_mv 10.3389/fimmu.2021.724060
identifier_str_mv Patarroyo ME, Patarroyo MA, Alba MP, Pabon L, Rugeles MT, Aguilar-Jimenez W, Florez L, Bermudez A, Rout AK, Griesinger C, Suarez CF, Aza-Conde J, Reyes C, Avendaño C, Samaca´ J, Camargo A, Silva Y, Forero M and Gonzalez E (2021) The First Chemically Synthesised, Highly Immunogenic Anti-SARS-CoV-2 Peptides in DNA Genotyped Aotus Monkeys for Human Use. Front. Immunol. 12:724060.
1664-3224
10.3389/fimmu.2021.724060
url https://hdl.handle.net/10495/36775
dc.language.iso.spa.fl_str_mv eng
language eng
dc.relation.ispartofjournalabbrev.spa.fl_str_mv Front. Immunol.
dc.relation.citationendpage.spa.fl_str_mv 16
dc.relation.citationissue.spa.fl_str_mv 724060
dc.relation.citationstartpage.spa.fl_str_mv 1
dc.relation.citationvolume.spa.fl_str_mv 12
dc.relation.ispartofjournal.spa.fl_str_mv Frontiers in Immunology
dc.rights.uri.*.fl_str_mv http://creativecommons.org/licenses/by/2.5/co/
dc.rights.uri.spa.fl_str_mv https://creativecommons.org/licenses/by/4.0/
dc.rights.accessrights.spa.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.coar.spa.fl_str_mv http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv http://creativecommons.org/licenses/by/2.5/co/
https://creativecommons.org/licenses/by/4.0/
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.extent.spa.fl_str_mv 16 páginas
dc.format.mimetype.spa.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Frontiers in immunology
dc.publisher.place.spa.fl_str_mv Lausana, Suiza
institution Universidad de Antioquia
bitstream.url.fl_str_mv https://bibliotecadigital.udea.edu.co/bitstreams/466adcfe-938f-4087-b1c3-86f680f1d1cc/download
https://bibliotecadigital.udea.edu.co/bitstreams/8553a277-6f15-462d-a5e9-c5090d89ae76/download
https://bibliotecadigital.udea.edu.co/bitstreams/462ab99e-a573-4a2b-9f95-aae20c477906/download
https://bibliotecadigital.udea.edu.co/bitstreams/187cae46-ef42-4b0d-89ea-ceff628127ef/download
https://bibliotecadigital.udea.edu.co/bitstreams/0f4eac2d-ba78-4958-99bc-bfc7542f992e/download
bitstream.checksum.fl_str_mv d7792b4b6a8aeccb891d0ca32a8cd8e1
54b25d00d9da26324cf2a57ee111c3e9
8a4605be74aa9ea9d79846c1fba20a33
95e20f67aec103c7fb0db042c6aa5954
50ea29bfba4556f66a5b744dd522455c
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional de la Universidad de Antioquia
repository.mail.fl_str_mv aplicacionbibliotecadigitalbiblioteca@udea.edu.co
_version_ 1851052563806289920
spelling Rugeles López, María TeresaAguilar Jiménez, WbeimarFlórez Álvarez, LizdanyPabón, LauraPatarroyo, Manuel ElkinPatarroyo, Manuel AlonsoAlba, Martha P.Bermúdez, AbrianaRout, Ashok k.Griesinger, CristinaSuarez Martínez, Carlos FernandoAza Conde, JorgeReyes, CesarAvendaño, CatalinaSamacá, JhoanCamargo, AnnySilva, YolandaForero, MarthaGonzález, EdgardoInmunovirología2023-10-03T15:48:19Z2023-10-03T15:48:19Z2021Patarroyo ME, Patarroyo MA, Alba MP, Pabon L, Rugeles MT, Aguilar-Jimenez W, Florez L, Bermudez A, Rout AK, Griesinger C, Suarez CF, Aza-Conde J, Reyes C, Avendaño C, Samaca´ J, Camargo A, Silva Y, Forero M and Gonzalez E (2021) The First Chemically Synthesised, Highly Immunogenic Anti-SARS-CoV-2 Peptides in DNA Genotyped Aotus Monkeys for Human Use. Front. Immunol. 12:724060.1664-3224https://hdl.handle.net/10495/3677510.3389/fimmu.2021.724060ABSTRACT: Thirty-five peptides selected from functionally-relevant SARS-CoV-2 spike (S), membrane (M), and envelope (E) proteins were suitably modified for immunising MHC class II (MHCII) DNA-genotyped Aotus monkeys and matched with HLA-DRb1* molecules for use in humans. This was aimed at producing the first minimal subunit-based, chemically synthesised, immunogenic molecules (COLSARSPROT) covering several HLA alleles. They were predicted to cover 48.25% of the world’s population for 6 weeks (short-term) and 33.65% for 15 weeks (long-lasting) as they induced very high immunofluorescent antibody (IFA) and ELISA titres against S, M and E parental native peptides, SARS-CoV-2 neutralising antibodies and host cell infection. The same immunological methods that led to identifying new peptides for inclusion in the COLSARSPROT mixture were used for antigenicity studies. Peptides were analysed with serum samples from patients suffering mild or severe SARS-CoV-2 infection, thereby increasing chemically-synthesised peptides’ potential coverage for the world populations up to 62.9%. These peptides’ 3D structural analysis (by 1 H-NMR acquired at 600 to 900 MHz) suggested structural functional immunological association. This first multi-protein, multi-epitope, minimal subunit-based, chemically-synthesised, highly immunogenic peptide mixture highlights such chemical synthesis methodology’s potential for rapidly obtaining very pure, highly reproducible, stable, cheap, easily-modifiable peptides for inducing immune protection against COVID-19, covering a substantial percentage of the human population.COL001244416 páginasapplication/pdfengFrontiers in immunologyLausana, Suizahttp://creativecommons.org/licenses/by/2.5/co/https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2The first chemically-synthesised, highly immunogenic anti-SARS-CoV 2 peptides in DNA genotyped aotus monkeys for human useArtículo de investigaciónhttp://purl.org/coar/resource_type/c_2df8fbb1https://purl.org/redcol/resource_type/ARThttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionSARS-CoV-2PéptidosPeptidesAnticuerpos ampliamente neutralizantesBroadly Neutralizing AntibodiesAnticuerpos ViralesAntibodies, ViralVacunas contra la COVID-19COVID-19 VaccinesCadenas HLA-DRB1HLA-DRB1 ChainsGlicoproteína de la Espiga del CoronavirusSpike Glycoprotein, CoronavirusVirosisVirus DiseasesFront. Immunol.16724060112Frontiers in ImmunologyPublicationORIGINALRugelesMaria_2021_TheFirstChemicallySynthesised.pdfRugelesMaria_2021_TheFirstChemicallySynthesised.pdfArtículo de Investigaciónapplication/pdf3431057https://bibliotecadigital.udea.edu.co/bitstreams/466adcfe-938f-4087-b1c3-86f680f1d1cc/downloadd7792b4b6a8aeccb891d0ca32a8cd8e1MD51trueAnonymousREADRugelesMaria_2021_First_Chemically_Synthesised.epubRugelesMaria_2021_First_Chemically_Synthesised.epubArtículo de Investigaciónapplication/epub+zip507917https://bibliotecadigital.udea.edu.co/bitstreams/8553a277-6f15-462d-a5e9-c5090d89ae76/download54b25d00d9da26324cf2a57ee111c3e9MD53falseAnonymousREADLICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://bibliotecadigital.udea.edu.co/bitstreams/462ab99e-a573-4a2b-9f95-aae20c477906/download8a4605be74aa9ea9d79846c1fba20a33MD52falseAnonymousREADTEXTRugelesMaria_2021_TheFirstChemicallySynthesised.pdf.txtRugelesMaria_2021_TheFirstChemicallySynthesised.pdf.txtExtracted texttext/plain100427https://bibliotecadigital.udea.edu.co/bitstreams/187cae46-ef42-4b0d-89ea-ceff628127ef/download95e20f67aec103c7fb0db042c6aa5954MD54falseAnonymousREADTHUMBNAILRugelesMaria_2021_TheFirstChemicallySynthesised.pdf.jpgRugelesMaria_2021_TheFirstChemicallySynthesised.pdf.jpgGenerated Thumbnailimage/jpeg14830https://bibliotecadigital.udea.edu.co/bitstreams/0f4eac2d-ba78-4958-99bc-bfc7542f992e/download50ea29bfba4556f66a5b744dd522455cMD55falseAnonymousREAD10495/36775oai:bibliotecadigital.udea.edu.co:10495/367752025-03-27 00:22:41.587http://creativecommons.org/licenses/by/2.5/co/open.accesshttps://bibliotecadigital.udea.edu.coRepositorio Institucional de la Universidad de Antioquiaaplicacionbibliotecadigitalbiblioteca@udea.edu.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